Sam Haidar

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

Nicholas Butowski, Howard Colman, John de Groot et al. · Neuro-Oncology · 2015 · 580 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma

Thomas Kaley, Patrick Y. Wen, David Schiff et al. · Neuro-Oncology · 2014 · 289 citations · Full text

Medicine, Oncology, Pharmacology +16

<i>EGFR</i> Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing

Joshua M. Francis, Cheng‐Zhong Zhang, Cécile L. Maire et al. · Cancer Discovery · 2014 · 279 citations · Full text

Medicine, Genetics, Oncology +17

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

Patrick Y. Wen, Mehdi Touat, Brian M. Alexander et al. · Journal of Clinical Oncology · 2019 · 155 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma

Andrew D. Norden, Keith L. Ligon, Samantha N. Hammond et al. · Neurology · 2014 · 118 citations · Full text

Medicine, Oncology, Surgery +16